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1. Introduction
  Idiopathic pulmonary fibrosis (IPF) is one of chronic, 
progressive interstitial lung diseases. The 5-year mortality 
rate for IPF patients is 50%-70%. IPF has a high mortality 
rate and lacks effective treatment methods in clinic[1]. It 
has been reported that compound Carapax trionycis (C. 
trionycis; Biejia in Chinese) formula can lower free radical-
induced oxidative damage to pulmonary tissue structure 
and decrease the activity of connective tissue growth 
factor within the pulmonary tissue by modulating free 
radical levels in vivo, thereby blocking the progression of 
pulmonary fibrosis[2]. In this study, we prepared a rat model 
of bleomycin-induced pulmonary fibrosis to investigate 
the effects of the compound C. trionycis formula against 
pulmonary fibrosis and the ultrastructural changes in 
pulmonary tissue after drug treatment.  
2. Materials and methods 
2.1. Rats 
  Sixty male Sprague-Dawley rats of SPF/VAF grade, 
weighing 200-220 g, were raised in a laboratory of biosafety 
level. The rats were on embryonic day 9 (E9 rats) and 
allowed free access to water. 
2.2. Drug
  Bleomycin (specification 15 mg/ampoule, lot No.: X22270), 
used to induce pulmonary fibrosis, was purchased from 
BLM Group (Osaka, Japan). Compound C. trionycis formula 
(lot No.: 2002050), used to treat pulmonary fibrosis, was 
produced by Inner Mongolia Furui Medical Science Co., Ltd 
(Huhhot, China).
2.3. Experimental design
   The rats were randomly divided into four groups, with 15 rats 
in each group. Following anesthesia by intraperitoneal injection 
of 1.5% (v/v) pentobarbital, the rats from each group were 
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administered bleomycin at a dose of 5 mg/kg body weight via 
the tracheal cannula. Massage was necessary to ensure the 
uniform distribution of bleomycin in the pulmonary tissue. 
The rats developed the signs of pulmonary fibrosis after 4 
weeks post the administration. In the model group, the rats 
were intragastrically administered 3 mL physiological saline 
once daily. In the compound C. trionycis formula high-, 
middle- and low-dose groups, the rats were intragastrically 
administered the compound C. trionycis formula respectively 
at a dose of 1.40, 0.70 and 0.35 g/kg body weight once daily. 
Five rats from each group were sacrificed on day 7, 14 
and 28 of the drug treatment, respectively. The pulmonary 
tissue was harvested for hematoxylin-eosin staining and 
transmission electron microscopy. Alveolitis and pulmonary 
fibrosis degree were assessed using the Szapiel’s method.
 
3. Results
3.1. Alleviating action of the compound C. trionycis formula 
against pulmonary fibrosis 
  Pulmonary fibrosis degree was relieved by the compound 
C. trionycis formula as displayed by hematoxylin-eosin 
staining. The details are shown in Table 1. On day 7 of the 
drug treatment, obvious acute pulmonary inflammation was 
observed in the rats of the model group, as manifested by 
swollen and widened alveolar septum with infiltration of 
a large number of mononuclear cells and a small number 
of neutrophil granulocytes, and by appearance of a few 
pulmonary interstitial fibroblasts. At this time, the degree 
of alveolar inflammation was milder in the compound C. 
trionycis formula middle- and low-dose groups than that in 
the model group and compound C. trionycis formula high-
dose group. 
  On day 14 of the drug treatment, the alveolar inflammation 
was alleviated in the model group compared with that on day 
7, and fibroblasts appeared in alveolar septum. However, the 
degree of both alveolar inflammation and pulmonary fibrosis 
was alleviated in the compound C. trionycis formula groups 
compared with that in the model group. 
  On day 28 of the drug treatment, fibrous tissue deposited 
in a large focus-like or diffuse manner in the model group, 
leading to alveolar fusion, narrow alveolar cavity, disordered 
lung structure, and lesions in larger than 51% of the whole 
lung area. In comparison, only a small amount of fibrous 
tissue deposited and the area of lesion accounted for less 
than 21% of the whole lung. 
3.2. Ultrastructural changes in pulmonary tissue after the 
7-day treatment with the compound C. trionycis formula
  On day 7 of the drug treatment, swollen type 栺 alveolar 
epithelial cells, slightly aggregated type 栻 alveolar 
epithelial cells, mitochondrial swelling, crista fragmentation, 
and an increased number of enlarged lamellar bodies 
were observed in the rats of the model group. Under 
a magnification of 20 000-30 000, uniform point-like 
particles in bundles were observed on the cross-section of 
pulmonary septum, and a lot of lysosomes, phagocytosed 
particles, lymphocytes and red blood cells were found in 
the macrophages. At this time, in the lungs of the treatment 
groups, type 栺 alveolar epithelial cells were slightly 
swollen, the aggregation of type 栻 alveolar epithelial cells 
was not obvious, and intracellular lamellar bodies had a 
regular morphology and decreased quantity and volume 
(Figure 1a).
3.3. Ultrastructural changes in pulmonary tissue after the 
14-day treatment of the compound C. trionycis formula 
Table 1 
Pulmonary fibrosis degree after different times of treatment with C. trionycis as displayed by hematoxylin-eosin staining. 
Group
Day 7 Day 14 Day 28
Alveolar inflammation Pulmonary fibrosis Alveolar inflammation Pulmonary fibrosis Alveolar inflammation Pulmonary fibrosis 
Model group + + - 依 + - + + +
High-dose group + - 依 依 - + +
Middle-dose group 依 - - 依 - +
Low-dose group 依 -/依 依 依 - +
The symbols -, 依, +, + +, and + + + represent a decreasing degree of pathological changes in order. 
Figure 1. Ultrastructural changes in pulmonary tissue after different times of treatment. 
On day 7 of the drug treatment, an increased number of lamellar bodies in type 栻 alveolar epithelial cells as well as intact capillary and alveolar 
basement membrane are observed in the compound C. trionycis formula group (×4 000) (Figure 1a). On day 14, alveolar cavities with little 
exudate and type 栻 alveolar epithelial cells which secrete well are observed in the compound C. trionycis formula group (×3 000) (Figure 1b). 
On day 28, collagen fibers are present around the pyknotic nuclei within the type 栻 alveolar epithelial cells in the model group (×4 000) (Figure 1c), 
while lamellar bodies in type 栻 alveolar epithelial cells are slightly larger, and no collagen fibers are present around the cells (×4 000) (Figure 1d). 
a b c d
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  On day 14 of the drug treatment, the lungs of the rats in 
the model group showed exfoliation of some type 栺 alveolar 
epithelial cells, alleviation of cell swelling and loose 
intercellular connections. Additionally, the aggregation 
of type 栻 alveolar epithelial cells became obvious and 
cellular nuclei exhibited an irregular morphology. Under a 
magnification of 20 000, collagen fibers in bundles appeared 
around the type 栻 alveolar epithelial cells and in the 
pulmonary interstitium. Comparatively, in the treatment 
groups, the number of pinocytotic vesicles in the type 栺 
alveolar epithelial cells increased, and no changes were 
found in the nuclei and nucleoli of type 栻 alveolar epithelial 
cells. Collagen fibers were not observed in the basement 
membrane and interstitium (Figure 1b).
3.4. Ultrastructural changes in pulmonary tissue after the 
28-day treatment of the compound C. trionycis formula 
  On day 28 of the drug treatment, degenerative type 栺 
alveolar epithelial cells, proliferative type 栻 alveolar 
epithelial cells, swelling, disintegration and exfoliation of 
endothelial cells, and incomplete basement membrane were 
observed in the lungs of the rats in the model group (Figure 
1c). However, in the treatment groups, the increase of type 
栻 alveolar epithelial cells were not obvious, a few tenuous 
collagen fibers were found in the interstitium, and a small 
number of lamellar bodies were tightly arranged in the cells 
(Figure 1d).
4. Discussion
  IPF is a progressive disease that finally leads to pulmonary 
dysfunction and is pathologically characterized by collagen 
deposition and destructed pulmonary tissue structure[3]. It 
has been reported that IPF patients should undergo lung 
transplantation as soon as possible after diagnosis because 
of a fact that medication therapy cannot prolong the life 
span of such patients at present[4-7]. However, the treatment 
is restricted by deficient donors and lifelong use of 
immunosuppressant after lung transplantation. Compound C. 
trionycis formula can strength body resistance to eliminate 
pathogenic factors and activate blood circulation to dissipate 
blood stasis; therefore, it is mainly used to treat pulmonary 
fibrosis. Recently, it has been reported that compound 
C. trionycis formula can effectively relieve pulmonary 
fibrosis[8]. 
  Compound C. trionycis formula, composed of C. trionycis 
(Turtle shell), Cordyceps (Chinese caterpillar fungus), Radix 
paeoniae Rubra (Red peony root), Rhizoma curcumae 
(Zedoray rhizome), Radix notoginseng (Sanchi), Placenta 
hominis (Human placenta), Radix codonopsis (Tangshen), 
Fructus forsythiae (Weeping forsythia capsule), Radix 
angelicae Sinensis (Chinese angelica), Radix isatidis (Isatis 
root) and Radix astragali (Milkvetch root), can enhance 
immunity, alleviate swelling, act against inflammation, 
inhibit fibroblast proliferation, and prevent and treat 
pulmonary fibrosis[9]. In the formula, C. trionycis can 
soften hard lumps and dispel nodes. According to the 
modern pharmacology, C. trionycis can depress secretion 
of Kupffer’s cells, activate hepatic stellate cells (HSC) by 
HSC autocrine pathway, and thereby inhibit activation of 
Kupffer’s cells and HSC vascular endothelial growth factors 
to resist pulmonary fibrosis[10]. Cordyceps is capable of 
eliminating phlegm, regulate immunity, promoting collagen 
degradation, expanding bronchi and preventing emphysema. 
Radix paeoniae Rubra and Radix notoginseng can activate 
blood and remove blood stasis, enhance immunity and 
resist inflammation. Placenta hominis can invigorate vital 
energy and benefit blood. Radix codonopsis is capable of 
nourishing qi to invigorate the spleen. Radix isatidis has 
antiviral, antibacterial, antipyretic and detoxicant activities. 
A combined use of these components has an effect against 
pulmonary fibrosis[11]. 
  In this study, the compound C. trionycis formula was used 
to treat IPF in rats. The observation on the ultrastructural 
changes showed that pulmonary fibrosis degree and 
collagen deposition were remarkably reduced. The results 
suggested that the formula can attenuate fiber accumulation 
and protect against pulmonary fibrosis, thereby playing an 
important role in prevention and treatment of IPF. 
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